Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results

Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease

(2018) Ron Brookmeyer et al.   Alzheimers & Dementia

What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public

(2018) Shana D. Stites et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer's Disease Biomarkers

(2018) Jalayne J. Arias et al.   JOURNAL OF LAW MEDICINE & ETHICS

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults

(2018) Jessica Mozersky et al.   JAMA Neurology

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review

(2018) Arno de Wilde et al.   Alzheimers Research & Therapy

Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial

(2018) Joshua D. Grill et al.   Alzheimers Research & Therapy

The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline

(2017) Taisei Wake et al.   INTERNATIONAL PSYCHOGERIATRICS

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability

(2016) Yen Ying Lim et al.   Alzheimers & Dementia

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review

(2016) S. A. S. A. Bemelmans et al.   Alzheimers Research & Therapy

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants

(2015) Kristin Harkins et al.   Alzheimers Research & Therapy

Public Perceptions of Presymptomatic Testing for Alzheimer Disease

(2014) Richard J. Caselli et al.   MAYO CLINIC PROCEEDINGS

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

(2013) Keith A. Johnson et al.   Alzheimers & Dementia

Disclosure of amyloid imaging results to research participants: Has the time come?

(2013) Jennifer H. Lingler et al.   Alzheimers & Dementia

Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education

(2013) K. A. Johnson et al.   JOURNAL OF NUCLEAR MEDICINE

Using AD biomarker research results for clinical care: A survey of ADNI investigators

(2013) M. B. Shulman et al.   NEUROLOGY

Monetary Costs of Dementia in the United States

(2013) Michael D. Hurd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease

(2013) Gaël Chételat et al.   NeuroImage-Clinical

Health Behavior Changes After Genetic Risk Assessment for Alzheimer Disease: The REVEAL Study

(2009) Serena Chao et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Disclosure ofAPOEGenotype for Risk of Alzheimer's Disease

(2009) Robert C. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE